1887

Abstract

Poliovirus (PV) infection causes severe paralysis, typically of the legs, by destruction of the motor neurons in the spinal cord. In this study, the relationship between PV replication in the spinal cord, damage in the motor neurons and poliomyelitis-like paralysis was analysed in transgenic mice expressing the human PV receptor (TgPVR21). First, a PV replicon encoding firefly luciferase in place of the capsid genes (PV-Fluc mc) was -encapsidated in 293T cells and the -encapsidated PV-Fluc mc (TE-PV-Fluc mc) was then inoculated into the spinal cords of TgPVR21 mice. TE-PV-Fluc mc was recovered with a titre of 6.3×10 infectious units ml, which was comparable to those of PV1 strains. TgPVR21 mice inoculated with TE-PV-Fluc mc showed non-lethal paralysis of the hindlimbs, with severity ranging from a decline in grip strength to complete flaccid paralysis. The replication of TE-PV-Fluc mc in the spinal cord reached peak levels at 10 h post-inoculation (p.i.), followed by the appearance of paralysis at as early as 12 h p.i., reaching a plateau at 16 h p.i. Histological analysis showed a correlation between the lesion and the severity of the clinical symptoms in most mice. However, severe paralysis could also be observed with an apparently low lesion score, where as few as 5.3×10 motor neurons (1.4 % of the susceptible cells in the lumbar cord) were infected by TE-PV-Fluc mc. These results indicate that PV replication in a small population of the motor neurons was critical for severe residual poliomyelitis-like paralysis in TgPVR21 mice.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82172-0
2006-11-01
2024-12-10
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/11/3317.html?itemId=/content/journal/jgv/10.1099/vir.0.82172-0&mimeType=html&fmt=ahah

References

  1. Abe S., Ota Y., Koike S., Kurata T., Horie H., Nomura T., Hashizume S., Nomoto A. 1995; Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice. Virology 206:1075–1083 [CrossRef]
    [Google Scholar]
  2. Ansardi D. C., Porter D. C., Morrow C. D. 1993; Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans . J Virol 67:3684–3690
    [Google Scholar]
  3. Arita M., Koike S., Aoki J., Horie H., Nomoto A. 1998; Interaction of poliovirus with its purified receptor and conformational alteration in the virion. J Virol 72:3578–3586
    [Google Scholar]
  4. Arita M., Horie H., Arita M., Nomoto A. 1999; Interaction of poliovirus with its receptor affords a high level of infectivity to the virion in poliovirus infections mediated by the Fc receptor. J Virol 73:1066–1074
    [Google Scholar]
  5. Arita M., Shimizu H., Miyamura T. 2004; Characterization of in vitro and in vivo phenotypes of poliovirus type 1 mutants with reduced viral protein synthesis activity. J Gen Virol 85:1933–1944 [CrossRef]
    [Google Scholar]
  6. Arita M., Shimizu H., Nagata N., Ami Y., Suzaki Y., Sata T., Iwasaki T., Miyamura T. 2005; Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 86:1391–1401 [CrossRef]
    [Google Scholar]
  7. Barclay W., Li Q., Hutchinson G., Moon D., Richardson A., Percy N., Almond J. W., Evans D. J. 1998; Encapsidation studies of poliovirus subgenomic replicons. J Gen Virol 79:1725–1734
    [Google Scholar]
  8. Bjugn R., Nyengaard J. R., Rosland J. H. 1997; Spinal cord transection – no loss of distal ventral horn neurons. Exp Neurol 148:179–186 [CrossRef]
    [Google Scholar]
  9. Bledsoe A. W., Gillespie G. Y., Morrow C. D. 2000; Targeted foreign gene expression in spinal cord neurons using poliovirus replicons. J Neurovirol 6:95–105 [CrossRef]
    [Google Scholar]
  10. Bodian D. 1949; Histopathologic basis of clinical findings in poliomyelitis. Am J Med 6:563–578 [CrossRef]
    [Google Scholar]
  11. Bodian D., Howe H. A. 1941; Neurotropism and the genesis of cerebral lesions in poliomyelitis: an experimental study. Bull Johns Hopkins Hosp 68:58–76
    [Google Scholar]
  12. Brown D. M., Cornell C. T., Tran G. P., Nguyen J. H. C., Semler B. L. 2005; An authentic 3′ noncoding region is necessary for efficient poliovirus replication. J Virol 79:11962–11973 [CrossRef]
    [Google Scholar]
  13. Campbell S. A., Lin J., Dobrikova E. Y., Gromeier M. 2005; Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J Virol 79:6281–6290 [CrossRef]
    [Google Scholar]
  14. Couderc T., Christodoulou C., Kopecka H., Marsden S., Taffs L. F., Crainic R., Horaud F. 1989; Molecular pathogenesis of neural lesions induced by poliovirus type 1. J Gen Virol 70:2907–2918 [CrossRef]
    [Google Scholar]
  15. Couderc T., Delpeyroux F., Le Blay H., Blondel B. 1996; Mouse adaptation determinants of poliovirus type 1 enhance viral uncoating. J Virol 70:305–312
    [Google Scholar]
  16. Couderc T., Guivel-Benhassine F., Calaora V., Gosselin A.-S., Blondel B. 2002; An ex vivo murine model to study poliovirus-induced apoptosis in nerve cells. J Gen Virol 83:1925–1930
    [Google Scholar]
  17. Crotty S., Hix L., Sigal L. J., Andino R. 2002; Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J Gen Virol 83:1707–1720
    [Google Scholar]
  18. Daley J. K., Gechman L. A., Skipworth J., Rall G. F. 2005; Poliovirus replication and spread in primary neuron cultures. Virology 340:10–20 [CrossRef]
    [Google Scholar]
  19. DeJesus N., Franco D., Paul A., Wimmer E., Cello J. 2005; Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence. J Virol 79:14235–14243 [CrossRef]
    [Google Scholar]
  20. Destombes J., Couderc T., Thiesson D., Girard S., Wilt S. G., Blondel B. 1997; Persistent poliovirus infection in mouse motoneurons. J Virol 71:1621–1628
    [Google Scholar]
  21. Dodd D. A., Niederoest B., Bloechlinger S., Dupuis L., Loeffler J.-P., Schwab M. E. 2005; Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem 280:12494–12502 [CrossRef]
    [Google Scholar]
  22. DuBridge R. B., Tang P., Hsia H. C., Leong P.-M., Miller J. H., Calos M. P. 1987; Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379–387
    [Google Scholar]
  23. Dufresne A. T., Gromeier M. 2004; A nonpolio enterovirus with respiratory tropism causes poliomyelitis in intercellular adhesion molecule 1 transgenic mice. Proc Natl Acad Sci U S A 101:13636–13641 [CrossRef]
    [Google Scholar]
  24. Evans D. T., Bricker J. E., Desrosiers R. C. 2004; A novel approach for producing lentiviruses that are limited to a single cycle of infection. J Virol 78:11715–11725 [CrossRef]
    [Google Scholar]
  25. Girard S., Couderc T., Destombes J., Thiesson D., Delpeyroux F., Blondel B. 1999; Poliovirus induces apoptosis in the mouse central nervous system. J Virol 73:6066–6072
    [Google Scholar]
  26. Gutiérrez A. L., Denova-Ocampo M., Racaniello V. R., del Angel R. M. 1997; Attenuating mutations in the poliovirus 5′ untranslated region alter its interaction with polypyrimidine tract-binding protein. J Virol 71:3826–3833
    [Google Scholar]
  27. Hagino-Yamagishi K., Nomoto A. 1989; In vitro construction of poliovirus defective interfering particles. J Virol 63:5386–5392
    [Google Scholar]
  28. Haller A. A., Stewart S. R., Semler B. L. 1996; Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J Virol 70:1467–1474
    [Google Scholar]
  29. Ida-Hosonuma M., Iwasaki T., Taya C., Sato Y., Li J., Nagata N., Yonekawa H., Koike S. 2002; Comparison of neuropathogenicity of poliovirus in two transgenic mouse strains expressing human poliovirus receptor with different distribution patterns. J Gen Virol 83:1095–1105
    [Google Scholar]
  30. Jackson C. A., Cobbs C., Peduzzi J. D., Novak M., Morrow C. D. 2001; Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis. Hum Gene Ther 12:1827–1841 [CrossRef]
    [Google Scholar]
  31. Jia X.-Y., Van Eden M., Busch M. G., Ehrenfeld E., Summers D. F. 1998; trans -Encapsidation of a poliovirus replicon by different picornavirus capsid proteins. J Virol 72:7972–7977
    [Google Scholar]
  32. Jia Q., Ohka S., Iwasaki K., Tohyama K., Nomoto A. 1999; Isolation and molecular characterization of a poliovirus type 1 mutant that replicates in the spinal cords of mice. J Virol 73:6041–6047
    [Google Scholar]
  33. Kaplan G., Racaniello V. R. 1988; Construction and characterization of poliovirus subgenomic replicons. J Virol 62:1687–1696
    [Google Scholar]
  34. Kärber G. 1931; Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharm 162:480–483 (in German [CrossRef]
    [Google Scholar]
  35. Kim D. W., Uetsuki T., Kaziro Y., Yamaguchi N., Sugano S. 1990; Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91:217–223 [CrossRef]
    [Google Scholar]
  36. Koike S., Taya C., Aoki J. & 7 other authors 1994; Characterization of three different transgenic mouse lines that carry human poliovirus receptor gene – influence of the transgene expression on pathogenesis. Arch Virol 139:351–363 [CrossRef]
    [Google Scholar]
  37. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685 [CrossRef]
    [Google Scholar]
  38. Lemon S. M., Honda M. 1997; Internal ribosome entry sites within the RNA genomes of hepatitis C virus and other flaviviruses. Semin Virol 8:274–288 [CrossRef]
    [Google Scholar]
  39. McComas A. J., Quartly C., Griggs R. C. 1997; Early and late losses of motor units after poliomyelitis. Brain 120:1415–1421 [CrossRef]
    [Google Scholar]
  40. Minor P. D. 1997; Poliovirus. In Viral Pathogenesis pp  555–574 Edited by Nathanson N., Ahmed R., Gonzalez-Scarano F., Griffin D. E., Holmes K. V., Murph F. A., Robinson H. L. Philadelphia, PA: Lippincott Williams & Wilkins;
    [Google Scholar]
  41. Nagata N., Iwasaki T., Ami Y. & 7 other authors 2001; Comparison of neuropathogenicity of poliovirus type 3 in transgenic mice bearing the poliovirus receptor gene and cynomolgus monkeys. Vaccine 19:3201–3208 [CrossRef]
    [Google Scholar]
  42. Nagata N., Shimizu H., Ami Y. & 7 other authors 2002; Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol 67:207–216 [CrossRef]
    [Google Scholar]
  43. Nathanson N., Bodian D. 1961; Experimental poliomyelitis following intramuscular virus injection. I. The effect of neural block on a neurotropic and a pantropic strain. Bull Johns Hopkins Hosp 108:308–319
    [Google Scholar]
  44. Pear W. S., Nolan G. P., Scott M. L., Baltimore D. 1993; Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:8392–8396 [CrossRef]
    [Google Scholar]
  45. Porter D. C., Ansardi D. C., Wang J., McPherson S., Moldoveanu Z., Morrow C. D. 1998; Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology 243:1–11 [CrossRef]
    [Google Scholar]
  46. Pyeon D., Lambert P. F., Ahlquist P. 2005; Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A 102:9311–9316 [CrossRef]
    [Google Scholar]
  47. Ren R., Racaniello V. R. 1992; Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J Virol 66:296–304
    [Google Scholar]
  48. Romanova L. I., Belov G. A., Lidsky P. V. & 7 other authors 2005; Variability in apoptotic response to poliovirus infection. Virology 331:292–306 [CrossRef]
    [Google Scholar]
  49. Saijo M., Qing T., Niikura M., Maeda A., Ikegami T., Sakai K., Prehaud C., Kurane I., Morikawa S. 2002; Immunofluorescence technique using HeLa cells expressing recombinant nucleoprotein for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Clin Microbiol 40:372–375 [CrossRef]
    [Google Scholar]
  50. Shaw G., Morse S., Ararat M., Graham F. L. 2002; Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16:869–871
    [Google Scholar]
  51. Svitkin Y. V., Maslova S. V., Agol V. I. 1985; The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies. Virology 147:243–252 [CrossRef]
    [Google Scholar]
  52. Svitkin Y. V., Cammack N., Minor P. D., Almond J. W. 1990; Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472→U. Virology 175:103–109 [CrossRef]
    [Google Scholar]
  53. Tolskaya E. A., Romanova L. I., Kolesnikova M. S., Ivannikova T. A., Agol V. I. 1996; Final checkpoint in the drug-promoted and poliovirus-promoted apoptosis is under post-translational control by growth factors. J Cell Biochem 63:422–431 [CrossRef]
    [Google Scholar]
  54. Utagawa E. T., Nakazawa E., Matsuo K., Oishi I., Takeda N., Miyamura T. 2002; Application of an automated specimen search system installed in a transmission electron microscope for the detection of caliciviruses in clinical specimens. J Virol Methods 100:49–56 [CrossRef]
    [Google Scholar]
  55. van der Werf S., Bradley J., Wimmer E., Studier F. W., Dunn J. J. 1986; Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A 83:2330–2334 [CrossRef]
    [Google Scholar]
  56. WHO 1990; Requirements for poliomyelitis vaccine (oral). WHO Tech Rep Ser 800:30–65
    [Google Scholar]
  57. Yanagiya A., Jia Q., Ohka S., Horie H., Nomoto A. 2005; Blockade of the poliovirus-induced cytopathic effect in neural cells by monoclonal antibody against poliovirus or the human poliovirus receptor. J Virol 79:1523–1532 [CrossRef]
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.82172-0
Loading
/content/journal/jgv/10.1099/vir.0.82172-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error